Comparative analysis of the effectiveness of iron therapy with a hepcidin-independent absorption mechanism in patients with chronic heart failure

The aim of this study is to describe anemia in chronic heart failure (CHF) and to evaluate the effectiveness of oral therapy with sucrosomial iron (SiderAL® Forte) in this group. Material and methods . The study included 56 patients with CHF and anemia. Results . Anemia in CHF corresponds to anemia of chronic disease (ACD) with the development of iron deficiency (ID) in 75% of patients. The use of sucrosomial iron leads to a significant increase in hemoglobin and serum ferritin levels, a decrease in the concentration of N-terminal pro-brain natriuretic peptide, an improvement in exercise tolerance, a reduction in the functional class of CHF, and a decrease in mortality over a 2-year follow-up period. Conclusion. The addition of iron preparations with hepcidin-independent absorption to standard CHF therapy shows a significant positive effect across all criteria and can be recommended for this category of patients in routine clinical practice.